Category Archives: ALS Treatment

A drug-addicted man wearing a protective face mask prepares a line of cocaine on his smartphone on ... [+] May 13, 2020, in a street of Lausanne, western Switzerland, amid the COVID-19 outbreak, caused by the novel coronavirus. Continue reading →

SALT LAKE CITY, May 26, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announcedits Australian subsidiary has completed over 50% of participant randomization in the Phase 2 RESCUE-ALS study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Amyotrophic Lateral Sclerosis (ALS). Continue reading →

May 27, 2020 17:14 ET | Source: Affiliated Managers Group, Inc. WEST PALM BEACH, Fla., May 27, 2020 (GLOBE NEWSWIRE) -- Affiliated Managers Group, Inc. (NYSE: AMG), a global asset management company, today announced with sadness the passing of Sean M Continue reading →

European authorities must step up efforts to screen babies for a multitude of genetic disorders, a panel of experts suggested during a May 14-15 online medical conference. The session was part of the 10th European Conference on Rare Diseases & Orphan Products (ECRD2020) which was to have occurred in Stockholm, but instead took place online via Zoom. Were interested in this topic because our community feels poorly served by newborn screening, said Nick Meade, policy director at Genetic Alliance UK, a national charity representing more than 230 British patient advocacy organizations. Continue reading →

Orphazyme A/S Company announcement No. 34/2020 Company Registration No. Continue reading →

Phil Green, Opinion contributor Published 6:30 a.m. MT May 21, 2020 ALS stands for amyotrophic lateral sclerosis, but is more commonly known as Lou Gehrig's disease. It's a neurodegerative disease that breaks down nerve cells in the brain and spinal cord, causing paralysis, according to the ALS Association website Continue reading →

Pat Emery, a 1983 Elder High School graduate, was diagnosed with amyotrophic lateral sclerosis (ALS) in March during the novel coronavirus pandemic. Emery's friends and family have started a fundraising campaign to get Pat a wheelchair-accessible van so he can make it back to The Pit to see Elder play football this season.(Photo: Provided) Pat Emerys speech is a little labored these days. Short breaths break up his sentences, but the occasional pause pales in comparison to the passion and energy that still define his voice Continue reading →

NEW YORK, May 5, 2020 /PRNewswire/ --Today, Target ALS and The Association for Frontotemporal Degeneration (AFTD) announced $5 million in funding awards for work by six research teams to aid in the discovery of biomarkers and viable treatments for ALS and frontotemporal degeneration (FTD). ALS and FTD (the most common dementia under 60) overlap in genetic causes and biological mechanisms. By joining forces, Target ALS and AFTD are leveraging the combined expertise of researchers in two fields, fueling collaboration in support of the most promising ideas Continue reading →

JERSEY CITY, N.J., May 5, 2020 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today reported that more than 5,000 people with amyotrophic lateral sclerosis (ALS) have received the treatment with RADICAVA (edaravone) in North America since the therapy was approved by the U.S. Food and Drug Administration (FDA) on May 5, 2017. Continue reading →

TORONTO, April 29, 2020 /CNW/ -Mitsubishi Tanabe Pharma CorporationCanada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA (edaravone) is now listed on the Rgie de l'assurance maladie du Qubec (RAMQ) formulary (special authorization). Continue reading →